Founded in August 2020, Zhejiang Boxiao Biopharmaceutical Co., Ltd. (BXBP) is at the forefront of biopharma innovation, with a robust discovery pipeline targeting major unmet needs. Our projects include HSP638, an anti-IGF-1R monoclonal antibody for Graves Disease (Phase II), TD-3, an AI-designed anti-gout molecule preparing for IND submission, and M00-2, a novel marine neurotoxin-derived sodium channel blocker for pain. To ensure financial resilience, BXBP also boasts a diversified, revenue-generating commercial portfolio: over 40 intermediates and APIs (six CFDA/USDMF-registered), plus advanced products such as antibody drug conjugates (ADCs), local anesthetics, ergot alkaloids, adrenaline products, antifungals, and dietary supplements. This balanced strategy delivers strong cash flow and mitigates risk, distinguishing BXBP from pre-revenue biotech firms and offering investors both near-term stability and high-growth potential.